跳至主要内容
临床试验/NCT00560053
NCT00560053已完成3 期

Multiple Myeloma 2000. Multicentric Evaluation of a Therapeutic Strategy Optimized in Multiple Myeloma. Analysis of Efficiency and Possible Pronostic Impact of Minimal Residual Disease (Measured By PCR And Citometry of Flow) in Patients With Complete Response

PETHEMA Foundation0 个研究点目标入组 500 人开始时间: 2000年1月1日最近更新:
适应症
相关药物

试验速览

阶段
3 期
状态
已完成
发起方
入组人数
500

研究概览

简要总结

The study objectives are to investigate the toxicity and the BUMEL response rate; in patients who reach the CR after autotransplantation, investigate if negativization of IF, influences in disease evolution; in patients in PR after autotransplantation, analyze if the second intensive procedure is capable of increasing the response rate and increasing the survival so that patients who reached the CR with the first transplantation; Patients with MM primarily resistant to the chemotherapy, investigate the efficacy of a double transplantation; patients submitted to double transplantation, control the efficacy of the second transplantation in front of allogenic transplantation.

研究设计

研究类型
Interventional
分配方式
Non Randomized
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
— 至 69 Years(Child, Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Less 70 years
  • Symptomatic MM (pain, anemia, infection, haemorrhage, loss of weight, hypercalcemia, extramedulary plasmocytoma, creatinine >2 mg/dl).
  • No previous chemotherapy

排除标准

  • >70 years
  • myeloma quiescent
  • cardiopathy
  • liver disfunction
  • Hepatitis B-C +
  • Previous chemotherapy

研究者

发起方
PETHEMA Foundation
申办方类型
Other

相似试验